Abstracts tagged "interleukins (IL)"

Abstract Number: 948 • 2013 ACR/ARHP Annual Meeting
Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5
Carolyn Cuff¹, Chung-Ming Hsieh², Suzanne Mathieu³, Anwar Murtaza⁴, Margaret Hugunin³, Shaughn Bryant³, Robert O'brien³, Lisa Olson⁵ and Jeffrey Voss³, ¹Immunology, AbbVie, Inc, Worcester, MA, ²Biologics, AbbVie Pharmaceuticals, Worcester, MA, ³Immunology, AbbVie Pharmaceuticals, Worcester, MA, ⁴Broad Institute, Cambridge, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Dual neutralization of TNF and IL-17 is hypothesized to provide greater efficacy in rheumatoid arthritis (RA) and inflammatory diseases compared to either monotherapy as…
Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting
Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger
Linda Rehaume¹, Stanislas Mondot², Daniel Aguirre de Cárcer², Jared Velasco¹, Helen Benham¹, Sumaira Hasnain³, Jaclyn Bowman¹, Merja Ruutu¹, Philip Hansbro⁴, Michael McGuckin³, Mark Morrison² and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²CSIRO Livestock Industries, Brisbane, Australia, ³Mater Medical Research Institute, Brisbane, Australia, ⁴Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting
Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
T. Noordenbos¹, I. Gofita¹, M. Alsina², E.W.M. Vogels³, A. A. te Velde³, J. D. Cañete⁴, Dominique L. Baeten⁵ and N. Yeremenko¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, ³Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…
Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
Abstract Number: 2503 • 2013 ACR/ARHP Annual Meeting
IL-17+ CD8+ T Cells Are Enriched In The Joints Of Patients With Psoriatic Arthritis and Correlate With Markers Of Disease Activity and Joint Damage Progression
Bina Menon^1,2, Nicola J. Gullick³, Hayley G. Evans⁴, Gina J. Walter⁴, Megha Rajasekhar⁴, Toby Garrood², Leonie S. Taams⁴ and Bruce W. Kirkham², ¹Centre for Cellular and Molecular Biology of Inflammation, King's College London, London, United Kingdom, ²Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, ³Rheumatology, King's College Hospital Foundation NHS Trust, London, United Kingdom, ⁴Centre for Molecular and Cellular Biology of Inflammation, King's College London, London, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) have clear differences in clinical, radiological and genetic features, suggesting that the immunopathology of the conditions may…
Abstract Number: 595 • 2013 ACR/ARHP Annual Meeting
Anemic Hypoxia Is Associated With Pulmonary Arterial Hypertension In Patients With Systemic Lupus Erythematosus
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Jin-Jung Choi⁴, Wan-Uk Kim² and Chul-Soo Cho⁵, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁵Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE), but its pathogenesis is still unclear. Hypoxia-induced pulmonary…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 410 • 2013 ACR/ARHP Annual Meeting
Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis
Lourdes Nuñez Atahualpa¹, Mauricio Figuroa Sanchez¹, Daniel Alberto Rocha Muñoz², Raul Vargas Ramirez³, Beatriz Teresita Martin Marquez⁴, Jorge Ivan Gamez Nava⁵, Laura González López⁶, Erika Martínez García³, Esther Sanchez Corona³, Marcelo Petri⁴, Rosa Navarro Hernandez³, Veronica Gonzalez Diaz⁷, Jorge Aguilar Arreola⁸, Ana Guisllaine Bernard Medina⁹, Alejandra Nuñez Atahualpa¹⁰, Javier Andrade Garduño¹⁰, Eduardo Gomez Bañuelos³ and Monica Vazquez Del Mercado^4,8, ¹Radiology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ²Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ³CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, ⁶Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, ⁷Reumatologia, Antiguo Hospital Civil de Guadalajara - Fray Antonio Alcalde, Guadalajara, Mexico, ⁸Rheumatology, Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, ⁹Rheumatology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ¹⁰Universidad Autónoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The main cause of death in rheumatoid arthritis patients are cardiovascular events which cannot be entirely explained by traditional risk factors, suggesting, that systemic…
Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 1653 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Synovial IL-21+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes
Maria C. Lebre¹, Pedro L. Vieira², Saïda Aarrass¹, Thomas Newsom-Davis², Paul Peter Tak³ and Gavin R. Screaton², ¹Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Immunology, Imperial College London, London, United Kingdom, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: IL-21 is a cytokine produced by activated CD4+ T cells and T follicular helper cells (TFh) that has been implicated in several autoimmune diseases…
Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Sang Jin Lee^1,2, Kyung Rok Kim³, Sang Hyun Joo³, Jae Myung Lee³, In Ah Choi³, Joo Youn Lee², Hyun Jung Yoo², Eun Young Lee⁴, Eun Bong Lee¹, Won Park⁵, Sung Hwan Park⁶, Seung-Cheol Shim⁷, Dae-Hyun Yoo⁸, Han Joo Baek⁹, Hyun Ah Kim¹⁰, Soo Kon Lee¹¹, Yun Jong Lee¹, Young Eun Park¹², Hoon-Suk Cha¹³ and Yeong Wook Song^2,3, ¹Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ²Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, ⁷Medicine, Rheumatology, Eulji University, Daejeon, South Korea, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹¹Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹²Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, ¹³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
Abstract Number: 1375 • 2013 ACR/ARHP Annual Meeting
Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33
Hyunho Lee^1,2, Jun-ichi Kashiwakura³, Masahiko Yanagisawa^1,2, Yuki Okamura^1,2, Takao Ishii², Masayuki Seki², Shu Saito², Yasuaki Tokuhashi², Chisei Ra¹ and Yoshimichi Okayama¹, ¹Allergy and Immunology Group, Nihon University School of Medicine, Tokyo, Japan, ²Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan, ³Laboratory for Allergic Disease, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan
Background/Purpose: Recent studies suggest that human synovial mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). Circulating IgG isotype autoantibodies and synovial…
Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
Abstract Number: 1168 • 2013 ACR/ARHP Annual Meeting
Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Hemophagocytic syndromes are caused by an uncontrolled systemic inflammatory response resulting in cytopenias, multisystem organ failure, and rapid death, often despite aggressive therapy. Macrophage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.